Navigation Links
CVBT Shareholders Vote for Change
Date:6/8/2013

LAS VEGAS, June 9, 2013 /PRNewswire/ -- CardioVascular BioTherapeutics, Inc. (CVBT) announced today that its shareholders have voted by over 60% to amend the bylaws of CVBT, remove specific directors of the Company and authorize the remaining directors to consider a financing proposal. 

The board members who have been removed effective June 7, 2013 are Daniel C. Montano, John (Jack) Jacobs, Ernest C. Montano, Viktoriya T. Montano, Ernest Montano III, and Joong Ki Baik.

The remaining two directors, Mickael A. Flaa and Grant Gordon, have appointed three new directors to the CVBT Interim Board of Directors: Calvin A. Wallen III, Jon Ross, and Robert Schleizer. The new directors bring financial, legal, securities and turnaround experience to CVBT's Board.

The Interim Board has met and ratified the bylaw amendments approved by the shareholders, authorized management to consider the financing proposal, terminated prior management and appointed Calvin A. Wallen III as Chairman of the Board, and Mickael A. Flaa as President and CFO.

More information on the new directors will be posted to CVBT's website in the very near future. http://www.cvbt.com 

About CardioVascular BioTherapeutics

CVBT is a biopharmaceutical company developing drug candidates with FGF-1 as its active pharmaceutical ingredient (API) for diseases characterized by inadequate blood flow to tissue or organs. The company is the sponsor of a Phase II trial to treat severe coronary heart disease (CVBT-141H), and has received FDA authorization for a Phase I trial to treat peripheral arterial disease (CVBT-141C). A Late-Stage trial to treat chronic diabetic foot ulcers (CVBT-141B) is planned pending FDA approval.

Forward Looking Statements
This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of CVBT drug candidates, market acceptance of CVBT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission.

Media Contacts:
Allison Caplan
CardioVascular BioTherapeutics, Inc.
(702) 839-7200
acaplan@cvbt.com

CVBT Mailing List
To be added to the CVBT Mailing List, please send your contact information to info@cvbtshareholder.com.


'/>"/>
SOURCE CardioVascular BioTherapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cytos Invites to the Annual Shareholders Meeting 2013
2. Royalty Pharma Recommends Elan Shareholders vote "NO" on each of the Elan Resolutions at the Elan extraordinary general meeting
3. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in AMAG Pharmaceuticals, Inc. of Class Action Lawsuit Investigation - AMAG
4. 3SBio Inc. Announces Shareholders Approval of the Amended Merger Agreement
5. Medifirst Solutions, Inc. Announces Update To Shareholders
6. TNI BioTech, Inc. Corporations CEO Issues Letter to Shareholders Discussing Recent Events
7. Valeant Pharmaceuticals To Webcast 2013 Annual Meeting Of Shareholders
8. Update to Shareholders on Dividend Payment: Medisafe 1 Technologies Corporation Files Corporate Action Form with FINRA for the Dividend Distribution to its Shareholders
9. 3SBio Inc. Announces Receipt of Amended "Going Private" Proposal at $16.70 Per ADS and Intent to Adjourn Extraordinary General Meeting of Shareholders
10. Faruqi & Faruqi, LLP is Investigating Peregrine Pharmaceuticals Inc. on Behalf of its Shareholders - PPHM
11. 3SBio Inc. Announces Extraordinary General Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
(Date:4/19/2017)... 19, 2017 Global Surgical Drainage Device Market: ... used to remove excess liquid and air. The fluid ... bile or lymph. Surgical drains are used in a ... orthopedics surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. Common ... prevent accumulation of fluid e.g. blood or pus. Surgical ...
(Date:4/19/2017)... 19, 2017 Companion ... response in pets such as canine, avian and ... various types such as Attenuated Live Vaccines, Conjugate ... Vaccines and Recombinant Vaccines. Attenuated live vaccines are ... bacteria, which have been weakend under laboratory conditions. ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... 2017 , ... The VIA Agency , a full-service ... Theravent, Inc. , the makers of a revolutionary new device clinically proven to ... working to expand distribution in anticipation of a national launch. VIA will be ...
(Date:4/21/2017)... ... April 21, 2017 , ... Alive for Wellness is a group ... mental health struggles. The Alive team uses advanced behavioral sciences treatment modalities to ... with a mental health struggle is based on 10 modalities of treatment ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... quality-based imaging practices, is seeking candidates to serve on its Accreditation and ... , “RadSite’s ultimate mission is improving image quality and reducing patient ...
(Date:4/21/2017)... ... April 21, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in ... of squashing a global crisis with solution to peace plan. Yisrayl says war has never ... plan is given by the Creator Himself. , Yisrayl says war drums are beating ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... good news for older shoulder replacement patients; post-operative recovery just might be even ... groups of patients presenting with osteoarthritis following surgery: 262 patients under 65 and ...
Breaking Medicine News(10 mins):